<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432018000200073</article-id>
<article-id pub-id-type="doi">10.7399/fh.10807</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Review of oritavancin for the treatment of acute bacterial skin and skin structure infections]]></article-title>
<article-title xml:lang="es"><![CDATA[Revisión crítica de la oritavancina en infecciones de la piel y tejidos blandos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Robles]]></surname>
<given-names><![CDATA[Ana Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López Briz]]></surname>
<given-names><![CDATA[Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fraga Fuentes]]></surname>
<given-names><![CDATA[María Dolores]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Asensi Díez]]></surname>
<given-names><![CDATA[Rocío]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sierra Sánchez]]></surname>
<given-names><![CDATA[Jesús Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario y Politécnico La Fe Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Valencia ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital La Mancha Centro Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Alcázar de San Juan Ciudad Real]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Regional Universitario Carlos Haya Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Málaga ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,AGS Norte de Cádiz Servicio de Farmacia, UGC Farmacia ]]></institution>
<addr-line><![CDATA[Cádiz ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2018</year>
</pub-date>
<volume>42</volume>
<numero>2</numero>
<fpage>73</fpage>
<lpage>81</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432018000200073&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432018000200073&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432018000200073&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To assess critically oritavancin, a second-generation lipo-glycopeptide, for the treatment of Acute Bacterial Skin and Skin Structure Infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus.  Method: An evaluation report of oritavancin in Acute Bacterial Skin and Skin Structure Infections was carried out according to the methodology of the Group for drug evaluation, standardization and research in drug selection of the Spanish Society of Hospital Pharmacy (SEFH)(1), with the MADRE 4.0 program. A search was made in PubMed, in the web www.clinicaltrials. gov, Embase, PubMed and UptoDate. The European Medication Agency and Food and Drug Administration evaluation reports were also used.  Results: Single-dose oritavancin demonstrated its non-inferiority efficacy versus vancomycin in Acute Bacterial Skin and Skin Structure Infections, with a similar safety profile. Its potential advantage over other therapeutic alternatives lies in its administration in single dose and in its no need for plasma levels monitoring, which would allow its administration on an outpatient basis. Regarding to the other alternative possibilities of oral (linezolid, tedizolid) or IM (teicoplanin) treatment, oritavancin would improve the adherence to the treatment. Although oritavancin could be more efficient in certain scenarios (outpatient treatment versus inpatient treatment with alternatives), there are no convincing studies in this regard so far. On the other hand, alternative drugs above-mentioned, can also allow outpatient treatment, reducing advantages of oritavancin and further increasing cost differences. Therefore, given that the efficacy is similar to the alternatives, a cost minimization analysis could be considered.  Conclusions: Oritavancin is comparable in terms of efficacy and safety to the existing alternatives in Acute Bacterial Skin and Skin Structure Infections, without improvements in the cost-effectiveness ratio, because of the proposed positioning is to consider it for the treatment of vancomycin-resistant enterococcal infection in adult patients when the use of linezolid or tedizolid is contraindicated.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Evaluar críticamente la oritavancina, lipoglicopéptido de segunda generación, para el tratamiento de la infección bacteriana aguda de la piel y tejidos blandos causada por bacterias Gram-positivas susceptibles, incluyendo Staphylococcus aureus resistente a meticilina.  Método: Se realizó un informe de evaluación según la metodología del Grupo de Evaluación de Novedades, Estandarización e Investigación en Selección de Medicamentos de la Sociedad Española de Farmacia Hospitalaria, con el programa MADRE 4.0. Se llevó a cabo una búsqueda en PubMed, en www.clinicaltrials.gov, Embase y UptoDate. También se utilizaron informes publicados de agencias de evaluación.  Resultados: La oritavancina en dosis única demostró no ser inferior a la vancomicina en Infección bacteriana aguda de la piel y tejidos blandos, con un perfil de seguridad similar. Sus ventajas potenciales frente a otras alternativas terapéuticas radicarían en su administración en dosis única y en la no necesidad de monitorización de los niveles plasmáticos (lo que posibilitaría su administración ambulatoria), y en la mejora de la adherencia. Aunque podría ser eficiente en determinados escenarios (tratamiento ambulatorio frente al hospitalario con las alternativas), no hay estudios convincentes en este sentido. Por otra parte, los fármacos alternativos por vía oral (linezolid, tedizolid) o IM (teicoplanina) pueden permitir también el tratamiento ambulatorio, reduciendo las ventajas de la oritavancina y agrandando las diferencias de coste. Dado que su eficacia es similar a las alternativas, cabría considerar un análisis de minimización de costes.  Conclusiones: La oritavancina es de una eficacia y seguridad comparables a las alternativas existentes en Infección bacteriana aguda de la piel y tejidos blandos y no mejora la relación coste-efectividad, por lo que el posicionamiento propuesto sería el tratamiento de la infección por enterococo resistente a vancomicina en pacientes adultos cuando esté contraindicado el uso de linezolid o tedizolid.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Oritavancin]]></kwd>
<kwd lng="en"><![CDATA[Bacterial skin diseases]]></kwd>
<kwd lng="en"><![CDATA[Glycopeptides]]></kwd>
<kwd lng="en"><![CDATA[Acute bacterial skin and skin structure infections]]></kwd>
<kwd lng="en"><![CDATA[Resistance]]></kwd>
<kwd lng="en"><![CDATA[Adherence]]></kwd>
<kwd lng="es"><![CDATA[Oritavancina]]></kwd>
<kwd lng="es"><![CDATA[Infecciones cutáneas]]></kwd>
<kwd lng="es"><![CDATA[Glicopéptidos]]></kwd>
<kwd lng="es"><![CDATA[Infecciones de piel y tejidos blandos]]></kwd>
<kwd lng="es"><![CDATA[Resistencia]]></kwd>
<kwd lng="es"><![CDATA[Adherencia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="">
<collab>FDA</collab>
<source><![CDATA[Guideline ABSSSI]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections (Internet)]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections (Internet)]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardona]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment]]></article-title>
<source><![CDATA[Clin Infect Dis Off Publ Infect Dis Soc Am]]></source>
<year>2015</year>
<volume>61</volume>
<numero>^sSupl. 2</numero>
<issue>^sSupl. 2</issue>
<supplement>Supl. 2</supplement>
<page-range>S69-78</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Edelsberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Taneja]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zervos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Haque]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends in US Hospital Admissions for Skin and Soft Tissue Infections]]></article-title>
<source><![CDATA[Emerg Infect Dis]]></source>
<year>2009</year>
<volume>15</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1516-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[ALLM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Parte II - Infecciones de tejidos blandos: Epidemiologia y clasificacion]]></article-title>
<source><![CDATA[Rev Panam Infectol]]></source>
<year>2013</year>
<volume>15</volume>
<numero>^sSupl. 1</numero>
<issue>^sSupl. 1</issue>
<supplement>Supl. 1</supplement>
<page-range>S39-41</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Llopis]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez-Castillo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Julian-Jimenez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ferre]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gamazo-Rio]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review of 1.250 episodes of skin and soft tissue infections attended at 49 hospital emergency departments]]></article-title>
<source><![CDATA[Rev Esp Quimioter Publ Of Soc Esp Quimioter]]></source>
<year>2014</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>115-21</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montejo Baranda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Onate Adrian]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Basterretxea Ozamiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Organizacion y tratamiento de la infeccion de piel y partes blandas. Protocolos de actuacion]]></source>
<year>2013</year>
<publisher-name><![CDATA[Hospital de Cruces (Osakidetza)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sartelli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Malangoni]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[May]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Viale]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kao]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Catena]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections]]></article-title>
<source><![CDATA[World J Emerg Surg]]></source>
<year>2014</year>
<volume>18</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>57</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Porras Leal]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Saenz Gutierrez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Calderon Jimenez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gijon Rodriguez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Protocolos SEMI infeccion de piel y partes blandas capitulo 5]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ostermann]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Avila]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McBride]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Blasi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study]]></article-title>
<source><![CDATA[Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis]]></source>
<year>2013</year>
<volume>19</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salgado Ordonez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Arroyo Nieto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano Serrano]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Hidalgo Conde]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Verdugo Carballeda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infecciones de piel y partes blandas]]></article-title>
<source><![CDATA[Med Clinica]]></source>
<year>2009</year>
<volume>133</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>552-64</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Currie]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Berni]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jenkins-Jones]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Poole]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Ouwens]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Driessen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2014</year>
<volume>23</volume>
<numero>349</numero>
<issue>349</issue>
<page-range>5493</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="book">
<collab>European Centre for Disease Prevention and Control</collab>
<source><![CDATA[Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Stockholm ]]></publisher-loc>
<publisher-name><![CDATA[ECDC]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[OrbactivR. Assessment report]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="">
<collab>FDA Center For Drug Evaluation And Research</collab>
<source><![CDATA[Clinical Review Orbactiv (NDA 206334)]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[OrbactivR. Summary of product characteristics (Internet)]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhanel]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
<name>
<surname><![CDATA[Schweizer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Karlowsky]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oritavancin: Mechanism of Action]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2012</year>
<volume>15</volume>
<numero>^s54(Supl. 3)</numero>
<issue>^s54(Supl. 3)</issue>
<supplement>54(Supl. 3)</supplement>
<page-range>S214-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Puigventos]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fraga]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Ortega]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Briz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Arocas]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Group for Innovation, Assessment, Standardisation and Research in the Selection of Drugs (GENESIS) of the Spanish Society of Hospital Pharmacy (SEFH). Support method for decision making in assessment and appraisal of medicines (MADRE)]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[SEFH]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ortega Eslava]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Marin Gil]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fraga Fuentes]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Briz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Puigventos Latorre]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Guia de evaluacion economica e impacto presupuestario en los informes de evaluacion de medicamentos. Guia practica asociada al programa MADRE v 4.0. (Internet)]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[SEFH]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dunbar]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Milata]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[McClure]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wasilewski]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SIMPLIFI Study Team. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2011</year>
<volume>55</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>3476-84</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corey]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Kabler]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mehra]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Overcash]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Porwal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>370</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2180-90</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corey]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Good]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Moeck]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wikler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study]]></article-title>
<source><![CDATA[Clin Infect Dis Off Publ Infect Dis Soc Am]]></source>
<year>2015</year>
<volume>60</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>254-62</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thom]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Halfpenny]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sulham]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Corey]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2015</year>
<volume>31</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1539-51</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bjornsson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug-induced liver injury: Hy&#8217;s rule revisited]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2006</year>
<volume>79</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>521-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[KJF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A US Hospital Economic Impact Model for Oritavancin In ABSSSI Patients With Risk of MRSA Infections]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2014</year>
<volume>17</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>A605</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[IS]]></given-names>
</name>
<name>
<surname><![CDATA[Lodise]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cyr]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolau]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis]]></article-title>
<source><![CDATA[Clin Drug Investig]]></source>
<year>2016</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>157-68</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[IS]]></given-names>
</name>
<name>
<surname><![CDATA[Cyr]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sulham]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of Oritavancin for the Treatment of Skin and soft Tissue Infections: A Uk Hospital Budget Impact Analysis]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2015</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>A233</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lodise]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Sulham]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic Impact of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Emergency Department or Observation Setting: Cost Savings Associated with Avoidable Hospitalizations]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ray]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
<name>
<surname><![CDATA[Suaya]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Baxter]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study]]></article-title>
<source><![CDATA[BMC Infect Dis]]></source>
<year>2013</year>
<volume>30</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>252</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
